• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三环苯甲酸 FTO 抑制剂的构效关系及抗白血病作用。

Structure-Activity Relationships and Antileukemia Effects of the Tricyclic Benzoic Acid FTO Inhibitors.

机构信息

State Key Laboratory of Drug Research, Centre for the Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

University of Chinese Academy of Sciences, Beijing 100049, China.

出版信息

J Med Chem. 2022 Aug 11;65(15):10638-10654. doi: 10.1021/acs.jmedchem.2c00848. Epub 2022 Jul 6.

DOI:10.1021/acs.jmedchem.2c00848
PMID:35793358
Abstract

The -methyladenosine (mA) demethylase FTO is overexpressed in acute myeloid leukemia (AML) cells and promotes leukemogenesis. We previously developed tricyclic benzoic acid FB23 as a highly potent FTO inhibitor in vitro. However, it showed a moderate antiproliferative effect on AML cells. In this work, we performed a structure-activity relationship study of tricyclic benzoic acids as FTO inhibitors. The analog exhibited excellent inhibitory effects on FTO similar to that of FB23 in vitro. In contrast to FB23, exerted a strong antiproliferative effect on AML cells. Like knock down, upregulated and expression and increased the protein abundance while it downregulated expression and decreased MYC protein abundance. These genes are key FTO targets in AML cells. Finally, treatment improved the survival rate of MONOMAC6-transplanted NSG mice. Collectively, our data suggest that targeting FTO with tricyclic benzoic acid inhibitors may be a potential strategy for treating AML.

摘要
  • 甲基腺嘌呤(mA)去甲基酶 FTO 在急性髓系白血病(AML)细胞中过表达,并促进白血病发生。我们之前开发了三环苯甲酸 FB23 作为体外高活性 FTO 抑制剂。然而,它对 AML 细胞表现出中等的增殖抑制作用。在这项工作中,我们对三环苯甲酸作为 FTO 抑制剂进行了构效关系研究。类似物 对 FTO 的抑制作用与 FB23 相似,体外活性优异。与 FB23 不同, 对 AML 细胞表现出强烈的增殖抑制作用。与 敲低类似, 上调 和 表达并增加蛋白丰度,同时下调 表达并降低 MYC 蛋白丰度。这些基因是 AML 细胞中 FTO 的关键靶点。最后, 处理可提高 MONOMAC6 移植 NSG 小鼠的存活率。总之,我们的数据表明,用三环苯甲酸抑制剂靶向 FTO 可能是治疗 AML 的一种潜在策略。

相似文献

1
Structure-Activity Relationships and Antileukemia Effects of the Tricyclic Benzoic Acid FTO Inhibitors.三环苯甲酸 FTO 抑制剂的构效关系及抗白血病作用。
J Med Chem. 2022 Aug 11;65(15):10638-10654. doi: 10.1021/acs.jmedchem.2c00848. Epub 2022 Jul 6.
2
Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties.理性设计 RNA 去甲基酶 FTO 抑制剂,增强抗白血病药物样性质。
J Med Chem. 2023 Jul 27;66(14):9731-9752. doi: 10.1021/acs.jmedchem.3c00543. Epub 2023 Jul 7.
3
Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia.小分子靶向致癌性 FTO 去甲基酶在急性髓系白血病中的作用。
Cancer Cell. 2019 Apr 15;35(4):677-691.e10. doi: 10.1016/j.ccell.2019.03.006.
4
[Research Progress of m6A Demethylase FTO and Its Inhibitors in Acute Myeloid Leukemia --Review].[6-甲基腺嘌呤去甲基化酶FTO及其抑制剂在急性髓系白血病中的研究进展——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Jun;31(3):902-906. doi: 10.19746/j.cnki.issn.1009-2137.2023.03.042.
5
Chemical Inhibitors Targeting the Oncogenic mA Modifying Proteins.靶向致癌 mA 修饰蛋白的化学抑制剂。
Acc Chem Res. 2023 Nov 7;56(21):3010-3022. doi: 10.1021/acs.accounts.3c00451. Epub 2023 Oct 27.
6
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-Methyladenosine RNA Demethylase.FTO作为一种N-甲基腺苷RNA去甲基化酶在急性髓系白血病中发挥致癌作用。
Cancer Cell. 2017 Jan 9;31(1):127-141. doi: 10.1016/j.ccell.2016.11.017. Epub 2016 Dec 22.
7
Saikosaponin D exhibits anti-leukemic activity by targeting FTO/mA signaling.柴胡皂苷 D 通过靶向 FTO/mA 信号通路发挥抗白血病活性。
Theranostics. 2021 Mar 31;11(12):5831-5846. doi: 10.7150/thno.55574. eCollection 2021.
8
The Yin and Yang of RNA Methylation: An Imbalance of Erasers Enhances Sensitivity to FTO Demethylase Small-Molecule Targeting in Leukemia Stem Cells.RNA 甲基化的阴阳两面:消去酶的失衡增强了白血病干细胞中 FTO 去甲基酶小分子靶向的敏感性。
Cancer Cell. 2019 Apr 15;35(4):540-541. doi: 10.1016/j.ccell.2019.03.011.
9
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/mA/PFKP/LDHB axis.R-2-羟基戊二酸通过靶向 FTO/mA/PFKP/LDHB 轴来抑制白血病中的有氧糖酵解。
Mol Cell. 2021 Mar 4;81(5):922-939.e9. doi: 10.1016/j.molcel.2020.12.026.
10
Glutathione-Bioimprinted Nanoparticles Targeting of N6-methyladenosine FTO Demethylase as a Strategy against Leukemic Stem Cells.靶向N6-甲基腺苷FTO去甲基化酶的谷胱甘肽生物印迹纳米颗粒作为对抗白血病干细胞的策略
Small. 2022 Apr;18(13):e2106558. doi: 10.1002/smll.202106558. Epub 2022 Feb 4.

引用本文的文献

1
Small-molecule and peptide inhibitors of m6A regulators.m6A调控因子的小分子和肽类抑制剂
Front Oncol. 2025 Aug 1;15:1629864. doi: 10.3389/fonc.2025.1629864. eCollection 2025.
2
Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy.发现一种有效的用于RNA去甲基化酶FTO的PROTAC降解剂作为抗白血病疗法。
Acta Pharm Sin B. 2024 Dec;14(12):5382-5392. doi: 10.1016/j.apsb.2024.07.016. Epub 2024 Jul 24.
3
Epigenetics-targeted drugs: current paradigms and future challenges.表观遗传学靶向药物:当前范例与未来挑战。
Signal Transduct Target Ther. 2024 Nov 26;9(1):332. doi: 10.1038/s41392-024-02039-0.
4
Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.解析表观转录组:癌症治疗和耐药性的新前沿。
Cell Commun Signal. 2024 Oct 21;22(1):513. doi: 10.1186/s12964-024-01854-w.
5
Diet-induced Obesity: Pathophysiology, Consequences and Target Specific Therapeutic Strategies.饮食诱导的肥胖:病理生理学、后果及靶向特异性治疗策略
Curr Protein Pept Sci. 2025;26(2):113-124. doi: 10.2174/0113892037329528240827180820.
6
Medicinal chemistry aspects of fat mass and obesity associated protein: structure, function and inhibitors.肥胖相关蛋白的脂肪质量的药物化学方面:结构、功能和抑制剂。
Future Med Chem. 2024 Aug 17;16(16):1705-1726. doi: 10.1080/17568919.2024.2380245. Epub 2024 Aug 5.
7
A new perspective on hematological malignancies: m6A modification in immune microenvironment.血液系统恶性肿瘤的新视角:免疫微环境中的m6A修饰
Front Immunol. 2024 May 28;15:1374390. doi: 10.3389/fimmu.2024.1374390. eCollection 2024.
8
Small molecule inhibitors targeting mA regulators.靶向 mA 调控因子的小分子抑制剂。
J Hematol Oncol. 2024 May 6;17(1):30. doi: 10.1186/s13045-024-01546-5.
9
Abnormal changes in metabolites caused by mA methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application.由mA甲基化修饰引起的代谢物异常变化:诱导免疫抑制肿瘤微环境形成的主要因素及其临床应用的潜在前景。
J Adv Res. 2025 Apr;70:159-186. doi: 10.1016/j.jare.2024.04.016. Epub 2024 Apr 25.
10
A covalent compound selectively inhibits RNA demethylase ALKBH5 rather than FTO.一种共价化合物选择性抑制RNA去甲基化酶ALKBH5而非FTO。
RSC Chem Biol. 2024 Feb 19;5(4):335-343. doi: 10.1039/d3cb00230f. eCollection 2024 Apr 3.